Enhanced sulfate pseudo-affinity chromatography using monolith-like particle architecture for purifying SARS-CoV-2

被引:0
作者
Kadoi, Kenji [1 ]
Toba, Junya [1 ]
Uehara, Ayana [1 ]
Isoda, Norikazu [2 ]
Sakoda, Yoshihiro [2 ]
Iwamoto, Eri [1 ]
机构
[1] JNC Corp, Yokohama R&D Ctr, 5-1 Ookawa,Kanazawa ku, Yokohama, Kanagawa 2368605, Japan
[2] Hokkaido Univ, Fac Vet Med, Lab Microbiol, Kita 18,Nishi 9,Kita Ku, Sapporo, Hokkaido 0600818, Japan
关键词
Monolith; SARS-CoV-2; Chromatography; Purification; pseudo-affinity; CELLUFINE SULFATE; INFLUENZA-A; VACCINE; VIRUSES; PURIFICATION;
D O I
10.1016/j.vaccine.2025.126951
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Traditional virus chromatographic purification face limitations owing to the small pore sizes of conventional resins, which restrict efficient virus binding. The newly developed MLP1000 DexS, a cellulose monolith-like particle (MLP) with large continuous pores (radius of 1.5 mu m) and a sulfate pseudo-affinity ligand, facilitates virus access to intraparticle surfaces and significantly enhances binding capacity. In this study, we investigated the effectiveness of MLP1000 DexS for purifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from Vero cells. Using a 0.29 mL column volume, we evaluated this resin through bind-elute mode chromatography under two load volume conditions (4.5 mL and 21 mL). MLP1000 DexS exhibited superior performance under high-loading conditions, achieving a high elution recovery of 59 % for the virus compared with that of 11-17 % for the commercial resins Cellufine Sulfate and Capto DeVirS. Additionally, the dsDNA removal capacity of MLP1000 DexS was 3.0-5.3-fold higher than that of the other resins. These findings suggest that MLP1000 DexS is an effective purification material for the downstream processing of live-attenuated and inactivated coronavirus vaccine production.
引用
收藏
页数:6
相关论文
共 26 条
  • [21] A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection
    Hassebroek, Anna M.
    Sooryanarain, Harini
    Heffron, Connie L.
    Hawks, Seth A.
    LeRoith, Tanya
    Cecere, Thomas E.
    Stone, William B.
    Walter, Debra
    Mahsoub, Hassan M.
    Wang, Bo
    Tian, Debin
    Ivester, Hannah M.
    Allen, Irving C.
    Auguste, Albert J.
    Duggal, Nisha K.
    Zhang, Chenming
    Meng, Xiang-Jin
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (02)
  • [22] Chimeric Virus-like Particle-Based COVID-19 Vaccine Confers Strong Protection against SARS-CoV-2 Viremia in K18-hACE2 Mice
    Kaewborisuth, Challika
    Wanitchang, Asawin
    Koonpaew, Surapong
    Srisutthisamphan, Kanjana
    Saenboonrueng, Janya
    Im-Erbsin, Rawiwan
    Inthawong, Manutsanun
    Sunyakumthorn, Piyanate
    Thaweerattanasinp, Theeradej
    Tanwattana, Nathiphat
    Jantraphakorn, Yuparat
    Reed, Matthew C.
    Lugo-Roman, Luis A.
    Hunsawong, Taweewun
    Klungthong, Chonticha
    Jones, Anthony R.
    Fernandez, Stefan
    Teeravechyan, Samaporn
    Lombardini, Eric D.
    Jongkaewwattana, Anan
    VACCINES, 2022, 10 (05)
  • [23] Late Breaking Abstract - Capture efficiency of mechanically nebulised synthetic nanoparticles, liposomes, SARS-CoV-2 virus-like particles, and infectious pseudotyped virions is influenced by particle surface charge
    Henderson, John
    Gross, Ruediger
    Moschos, Sterghios
    Ali, Saqib
    Mantso, Theodora
    Wright, Ed
    Mueller, Janis
    Muench, Jan
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [24] Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines
    Dube, Charlotte
    Paris-Robidas, Sarah
    Andreani, Guadalupe
    Gutzeit, Cindy
    D'aoust, Marc-Andre
    Ward, Brian J.
    Trepanier, Sonia
    VACCINE, 2022, 40 (30) : 4017 - 4025
  • [25] Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines
    Dube, Charlotte
    Paris-Robidas, Sarah
    Andreani, Guadalupe
    Gutzeit, Cindy
    D'aoust, Marc-Andre
    Ward, Brian J.
    Trepanier, Sonia
    VACCINE, 2022, 40 (29) : 4017 - 4025
  • [26] High-Yield Production of Chimeric Hepatitis E Virus-Like Particles Bearing the M2e Influenza Epitope and Receptor Binding Domain of SARS-CoV-2 in Plants Using Viral Vectors
    Mardanova, Eugenia S.
    Kotlyarov, Roman Y.
    Stuchinskaya, Maya D.
    Nikolaeva, Lyudmila I.
    Zahmanova, Gergana
    Ravin, Nikolai V.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)